"In vivo RNAi screening to identify new therapeutic targets for the treatment of patients with liver failure and liver cancer"

Conférence présentée en collaboration avec la German Research Foundation et le Consulat générale d'Allemagne à Montréal.

Date: lundi 9 mai 2016, 17h30 à 20h30

Lieu: salle S1-151, pavillon Jean-Coutu

 

Lars Zender, Gottfried Wilhelm Leibniz Prize 2014

Conférence prononcée en anglais, suivie d'une réception.

Entrée libre. RSVP : http://www.eventbrite.com/e/german-research-foundation-leibniz-lecture-lars-zender-tickets-24815614170

Sujet: It is predicted that cases of liver disease will double by 2025, resulting in 25 million US Americans suffering from chronic liver failure and liver cirrhosis. Chronic liver failure can be treated by liver transplantation, however, the number of donor organs is limited and more than 1.5 million people worldwide are dying of liver failure each year. Liver disease is further complicated by the fact that liver cirrhosis represents the most important risk factor for the development of liver cancer, hepatocellular carcinoma (HCC).  HCC is a highly aggressive cancer which makes it the second most common cause of cancer death worldwide. You are invited to join us on May 9, 2016, to learn about a new technology that identifies therapeutic targets for the treatment of liver failure or liver cancer developed by the award winning Prof. Lars Zender. He will discuss the role of academic drug discovery infrastructures for rapidly translating validated therapeutic target structures into clinical applications. Prof. Zender will show an example of a novel and promising drug for the treatment of liver cancer which entered clinical trials only 13 months after completion of preclinical testing.